Lombard Medical Technologies (LMT) is a specialist cardiovascular device and polymer coatings company which focuses on discovering, developing and commercialising innovative products that address the unmet needs of medical professionals across the world.

 

LMT’s technological expertise results in products with design advantages over the competition.

 

Headquartered near Oxford, in the UK, LMT has made considerable progress with its flagship product – the Aorfix™ endovascular stent graft for Abdominal Aortic Aneurysm (AAA) disease.

 

Aorfix™  addresses a growing market forecast to exceed $1 billion by 2010. Its unique design incorporating durability, good fixation and unparalleled flexibility complies with the changing human anatomy and makes it suitable for the treatment of most AAA’s.

 

Aorfix™ endovascular stent graft is CE Mark approved in the EU and has obtained IDE approval from the FDA in connection with US clinical trials.

 

Updated December 2009

 


LSE Share Price

   Connecting
 

Click below for full brochure

Request Marketing Literature

 

NOW AVAILABLE

Watch the Aorfix Breakfast Symposium at CIRSE 2009;  presentations by Dr John Hardman RUHBath and Dr Jorge Tessarek, Munster.  Click link 2009/cirse/lombard/